# Molecular Heterogeneity and Response to Neoadjuvant Human Epidermal Growth Factor Receptor 2 Targeting in CALGB 40601, a Randomized Phase III Trial of Paclitaxel Plus Trastuzumab With or Without Lapatinib

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/molecular-heterogeneity-and-response-to-neoadjuvant-human-epidermal-growth/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Lisa A. Carey,Donald A. Berry,Constance Cirrincione,William T. Barry,Brandelyn N. Pitcher,Lyndsay N. Harris,David W. Ollila,Ian E. Krop,N. Lynn Henry,Douglas Weckstein,Carey K. Anders,Baljit Singh,Katherine A. Hoadley,Michael D. Iglesia,Maggie C.U. Cheang,Charles M. Perou,Eric P. Winer,Clifford A. Hudis |
| Citations | 439 |
| DOI | 10.1200/jco.2015.62.1268 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | true |
| OA Status | bronze |
| OA URL | https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2015.62.1268?role=tab |
| OpenAlex ID | https://openalex.org/W2162982444 |
| PMID | 26527775 |
| Type | article |
| Year | 2015 |

## Paper authors

- [Lisa A. Carey](https://scholariq.org/researchers/lisa-a-carey/)
- [N. Lynn Henry](https://scholariq.org/researchers/n-lynn-henry/)
- [Clifford A. Hudis](https://scholariq.org/researchers/clifford-a-hudis/)

## Paper journal

- [Journal of Clinical Oncology](https://scholariq.org/journals/journal-of-clinical-oncology/)

## Paper primary topic

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)

## Paper topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.